Skip to main content
SpringerLink
Log in
Book cover

Hyperparathyroidism pp 157–167Cite as

Normocalcemic Primary Hyperparathyroidism

  • Chapter
  • First Online:

  • 828 Accesses

Abstract

Over the past two decades, normocalcemic primary hyperparathyroidism (NPHPT) has emerged as a new subset of primary hyperparathyroidism which, after exclusion of secondary hyperparathyroidism, is characterized by consistent normocalcemia with elevated parathyroid hormone levels. Population-based epidemiologic data lack reproducibility and generalizability. NPHPT has primarily been diagnosed in subjects referred for evaluation of symptoms related to this metabolic disease. However, an asymptomatic phase of the disease does appear to occur in the general population, suggesting that primary hyperparathyroidism is a spectrum that encompasses both normocalcemia and hypercalcemia that occurs in parallel with, but is not necessarily linked to, silent and symptomatic disease. In the current absence of good evidence, management recommendations for asymptomatic PHPT cannot be applied to patients with NPHPT.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Silverberg SJ, Bilezikian JP. “Incipient” primary hyperparathyroidism: a “Forme Fruste” of an old disease. J Clin Endocrinol Metab. 2003;88:5348–52.

    Article  PubMed  CAS  Google Scholar 

  2. Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, et al. Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab. 2013;98:2734–41.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Bilezikian JP, Silverberg SJ. Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metab. 2010;54:106–9.

    Article  Google Scholar 

  4. Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16:33–9.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Eastell R, Brandi ML, Costa AG, D’amour P, Shoback DM, Thakker RV. Diagnosis of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3570–9.

    Article  PubMed  CAS  Google Scholar 

  6. Ong GS, Walsh JP, Stuckey BG, et al. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab. 2012;97:3138–45.

    Article  PubMed  CAS  Google Scholar 

  7. Björkman M, Sorva A, Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr. 2009;48:160–6.

    Article  PubMed  Google Scholar 

  8. Fillée C, Keller T, Mourad M, Brinkmann T, Ketelslegers JM. Impact of vitamin D-related serum PTH reference values on the diagnosis of mild primary hyperparathyroidism, using bivariate calcium/PTH reference regions. Clin Endocrinol (Oxf). 2012;76:785–9.

    Article  Google Scholar 

  9. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1–130.

    Google Scholar 

  10. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(4 Suppl 3):S1–201.

    Google Scholar 

  11. Lundgren E, Hagström EG, Lundin J, Winnerbäck K, Roos J, Ljunghall S, Rastad J. Primary hyperparathyroidism revisited in menopausal women with serum calcium in the upper normal range at population-based screening 8 years ago. World J Surg. 2002;26(8):931–6.

    Article  PubMed  Google Scholar 

  12. Misra B, Silverberg SJ, Bilezikian JP. Prevalence and demographics of asymptomatic normocalcemic hyperparathyroidism in the United States. Program of the 30th Annual Meeting of the American Society of Bone and Mineral Research. Montreal; 2008.

    Google Scholar 

  13. Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012;42(3):764–6.

    Article  PubMed  CAS  Google Scholar 

  14. Berger C, Langsetmo L, Hanley D, Hadachi J, Kovacs C, Brown J, Josse R, Goltzman D. Relative prevalence of normocalcemic and hypercalcemic hyperparathyroidism in a community-dwelling cohort. 33rd Annual Meeting of the American Society of Bone and Mineral Research. San Diego; 2011. abstract pSU0173.

    Google Scholar 

  15. Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, et al. Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect. 2015;4(3):172–8.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Amaral LM, Queiroz DC, Marques TF, et al. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012;3:128–352.

    Google Scholar 

  17. Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117:861–3.

    Article  PubMed  Google Scholar 

  18. Campennì A, Ruggeri RM, Sindoni A, Giovinazzo S, Calbo E, Ieni A, Calbo L, Tuccari G, Baldari S, Benvenga S. Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab. 2012;30:367–72.

    Article  PubMed  Google Scholar 

  19. Lowe H, McMahon DJ, Rubin MR, et al. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92:3001–5.

    Article  PubMed  CAS  Google Scholar 

  20. Cakir I, Unluhizarci K, Tanriverdi F, et al. Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine. 2012;42(2):419–22.

    Article  PubMed  CAS  Google Scholar 

  21. Wade TJ, Yen TW, Amin AL, Wang TS. Surgical management of normocalcemic primary hyperparathyroidism. World J Surg. 2012;36:761–6.

    Article  PubMed  Google Scholar 

  22. Liu J-M, Cusano NE, Silva BC, Zhao L, He X-Y, Tao B, et al. Primary hyperparathyroidism: a tale of two cities revisited – New York and Shanghai. Bone Res. 2013;2:162–9.

    Article  Google Scholar 

  23. Koumakis E, Souberbielle J-C, Payet J, Sarfati E, Borderie D, Kahan A, et al. Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int. 2014;25:1963–8.

    Article  PubMed  CAS  Google Scholar 

  24. Rao DS, Wilson RJ, Kleerekoper M, Parfitt AM. Lack of biochemical progression or continuation of accelerated bone loss in mild asymptomatic primary hyperparathyroidism: evidence for biphasic disease course. J Clin Endocrinol Metab. 1988;67(6):1294–8.

    Article  PubMed  CAS  Google Scholar 

  25. Yagi S, Aihara K, Kondo T, et al. High serum parathyroid hormone and calcium are risk factors for hypertension in Japanese patients. Endocr J. 2014;61:727–33.

    Article  PubMed  CAS  Google Scholar 

  26. Jorde R, Bonaa KH, Sundsfjord J. Population based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol. 1999;141:350–7.

    Article  PubMed  CAS  Google Scholar 

  27. Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, et al. Is normocalcemic primary hyperparathyroidism: harmful or harmless? J Clin Endocrinol Metab. 2015;100(6):2420–4.

    Article  PubMed  CAS  Google Scholar 

  28. Tordjman KM, Yaron M, Izkhakov E, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162:925–33.

    Article  PubMed  CAS  Google Scholar 

  29. Hedbäck G, Odén A. Increased risk of death from primary hyperparathyroidism – an update. Eur J Clin Invest. 1998;28:271–6.

    Article  PubMed  Google Scholar 

  30. Silverberg SJ, Clarke BL, Peacock M, Bandeira F, Boutroy S, Cusano NE, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: Proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580–94.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of Interest

All authors state that they have no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Internal Medicine, Mayo College of Medicine, Mayo Clinic, Rochester, MN, USA

    Jad G. Sfeir MD & Matthew T. Drake MD, PhD

Authors
  1. Jad G. Sfeir MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew T. Drake MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew T. Drake MD, PhD .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Rochester, Minnesota, USA

    Ann E. Kearns

  2. Mayo Clinic, Rochester, Minnesota, USA

    Robert A. Wermers

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Sfeir, J.G., Drake, M.T. (2016). Normocalcemic Primary Hyperparathyroidism. In: Kearns, A., Wermers, R. (eds) Hyperparathyroidism. Springer, Cham. https://doi.org/10.1007/978-3-319-25880-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-25880-5_18

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-25878-2

  • Online ISBN: 978-3-319-25880-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation